# Romiplostim Plus Dexamethasone vs Dexamethasone in Patients With Newly Diagnosed Primary Immune Thrombocytopenia

> **NCT05325593** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Fundación Pública Andaluza para la gestión de la Investigación en Sevilla** · enrollment: 129 (actual)

## Conditions studied

- Primary Immune Thrombocytopenia

## Interventions

- **DRUG:** romiplostim plus dexamethasone
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT05325593
- **Lead sponsor:** Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-12-02
- **Primary completion:** 2026-10-24
- **Final completion:** 2026-10-24
- **Target enrollment:** 129 (ACTUAL)
- **Last updated:** 2025-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05325593

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05325593, "Romiplostim Plus Dexamethasone vs Dexamethasone in Patients With Newly Diagnosed Primary Immune Thrombocytopenia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05325593. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*